Dacomitinib: all 48 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingNCT06486142Phase 3
• First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsRecruitingNCT05271916Phase 1/2
• PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsCompletedNCT04511533Phase 4Results posted
• Evaluate Severe Hepatic Impairment on Dacomitinib PKCompletedNCT03865446Phase 1Results posted
• A Rollover Protocol of Dacomitinib For Patients In JapanCompletedNCT02382796Phase 2Results posted
• A Phase II Study of Dacomitinib in Progressive Brain MetastasesTerminatedNCT02047747Phase 2Results posted
• Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01918761Phase 1Results posted
• A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01858389Phase 2Results posted
• ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.CompletedNCT01774721Phase 3Results posted
• Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.CompletedNCT01520870Phase 2Results posted
• Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PROCompletedNCT01465802Phase 2Results posted
• ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerCompletedNCT01360554Phase 3Results posted
• A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung CancerCompletedNCT01121575Phase 1Results posted
• PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic CancerCompletedNCT01000025Phase 3Results posted
• Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The LungCompletedNCT00818441Phase 2Results posted
• A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenCompletedNCT00769067Phase 2Results posted
• Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell CancerCompletedNCT00768664Phase 2Results posted
• A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer PatientsCompletedNCT00728468Phase 1Results posted
• Trial Of PF-00299804 In Patients With Advanced Refractory Lung CancerCompletedNCT00553254Phase 2Results posted
• PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And ErlotinibCompletedNCT00548093Phase 2Results posted
• Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging BiomarkersActive, not recruitingNCT04946968Phase 2
• Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsStatus unknownNCT04811001Phase 2
• Central Nervous System(CNS) Efficacy of DacomitinibStatus unknownNCT04675008Phase 2
• Dacomitinib in Lung Cancer With Uncommon EGFR MutationsActive, not recruitingNCT04504071Phase 2
• An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain MetastasesStatus unknownNCT04339829Phase 2
• Phase 2 Study of Dacomitinib in NSCLCActive, not recruitingNCT04027647Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerCompletedNCT03810807Phase 1
• A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.CompletedNCT03755102Early Phase 1
• Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell CancerStatus unknownNCT02268747Phase 2
• Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy VolunteersCompletedNCT02097433Phase 1
• A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy VolunteersCompletedNCT01796327Phase 1
• Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedNCT01737008Phase 1
• Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the PenisCompletedNCT01728233Phase 2
• Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)CompletedNCT01702506Phase 1
• A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic ImpairmentCompletedNCT01571388Phase 1
• A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT01484847Not applicable
• PF-00299804 in Patients With Head and Neck Squamous Cell CarcinomaCompletedNCT01449201Phase 2
• -02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerTerminatedNCT01441128Phase 1
• PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric CancerCompletedNCT01152853Phase 2
• Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative TreatmentCompletedNCT01116843Phase 1/2
• PF-00299804 in Adult Patients With Relapsed/Recurrent GlioblastomaCompletedNCT01112527Phase 2
• A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804TerminatedNCT00971191Phase 1
• A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid TumorsCompletedNCT00783328Phase 1
• A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 WeeksCompletedNCT00728390Phase 1
• Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid TumorsCompletedNCT00225121Phase 1

← Dacomitinib overview